KABS Pharmaceutical Services Ransomware Attack
kabs.comRansomed
About this victim
kabs.com Revenue $27.2 Million KABS Laboratories is a Canadian pharmaceutical CDMO founded in 1997 in Saint-Hubert, Quebec by Dr. Jean-Simon Blais and Dr. Gérard Akinocho, with 150+ specialists serving clients in 28 countries. It is a WHO prequalified Quality Control Laboratory audited by Health Canada, USFDA and EU QPs, offering aseptic manufacturing from 100 to 100,000 vials per batch. In 2021 it received CAD 54.2 million from Canada's Strategic Innovation Fund to expand fill-and-finish to 30 million vials per year and build a bioprocessing plant for monoclonal antibodies. Through joint venture MendeliKABS it developed MDK-Nitisinone, an orphan drug for tyrosinemia type 1, priced 10 times lower than the Swedish competitor and approved in Europe, UK, Brazil, China and Algeria. The company also runs an African quality control office in Benin.
Overview
View group profileDomain
kabs.com
Industry
Healthcare
Country
Canada
Discovered
15 days ago
Attack date
Nov 2, 2026
Confidence
70%
Severity
Medium
Status
Claimed
Threat group
thegentlemenTotal victims
1,114
First seen
Nov 2025
Last seen
Nov 2026
Group status
active
Sophistication
0
Impact score
111
Threat level
7.1/10Status breakdown
Victim's position within group
Industry
Healthcare
Known target sector
Country
Canada
Frequently targeted country
Other victims
View all (1114)Same group · thegentlemen
Group activity
Monthly attacks · thegentlemen
1,114
total · avg 85.7/mo